Carbonic anhydrase IX as a predictive biomarker of response to kidney cancer therapy.
Signoretti
Sabina
S
Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. ssignoretti@partners.org
Regan
Meredith
M
Atkins
Michael
M
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000951:Antigens, Neoplasm / Q000378:metabolism*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000071231:Carbonic Anhydrase IX; D002256:Carbonic Anhydrases / Q000378:metabolism*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000201:enzymology; D005260:Female; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D008297:Male; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D007376:Interleukin-2; C089226:CA9 protein, human; D000071231:Carbonic Anhydrase IX; D002256:Carbonic Anhydrases